Regulatory, legal and policy aspects

Workpackage #8

Regulatory, legal and policy aspects

iCARE4CVD’s vision to pave the way to better care for individuals with
CVD could not be realised without careful insight into the regulatory, legal,
reimbursement, and policy landscape relevant to CVD. By defining a
roadmap, framework, and a strategy for biomarker and medical AI
developments that is safe, ethical, and successful, WP8 will aim to
facilitate a successful adaption and implementation of iCARE4CVD’s
medical tools.

Meet our team

TNO

Robin Mischa van Stokkum

Researcher Digital Health and Coordinator TNO Health & Work AI Lab
Read more
Kirsten Budig

Novo Nordisk

Kirsten Budig

Senior Public Affairs Manager
Read more

Scientific Institute for Health Economics and Health Systems Research

Ines Weinhold

Managing Director at WIG2
Read more

WIG2

Rebekka Mumm

Head of Health Economics
Read more

WIG2

Franziska Theile

Research Associate
Read more

TNO

Gabriela Bodea, MA

Dutch Organisation for Applied Research
Read more
Get updated

Our related news

Read more

4 May, 2026

The Precision Moonshot: Redefining Cardiovascular Care for 85 Million Europeans

Cardiovascular disease affects 85 million Europeans, yet most patients are still treated..
Read more

30 April, 2026

The right treatment for the right patient: Rethinking heart failure care

Heart failure is a leading cause of hospitalisation in Europe, especially among..
Read more

29 April, 2026

“Suddenly, you are a patient 24 hours a day” – A patient perspective on living with heart failure

Heart failure affects millions worldwide, yet no two experiences are the same,..
Read more

Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.

Funding acknowledgment

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) and Breakthrough T1D under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe.

Disclaimer

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Quick Links